Adult rat dorsal root ganglion (DRG) sensory neurons
100 ng/ml
24–30 h
BT13 promoted neurite growth from peptidergic sensory neurons but did not affect neurite initiation
Front Pharmacol. 2017 Jun 21;8:365
MG87RET murine fibroblasts
0.1–50 µM
BT13 dose-dependently activated luciferase with EC50=17.4 µM, inducing an 11.6-fold increase in luciferase activity
Front Pharmacol. 2017 Jun 21;8:365
RET-knockout embryonic midbrain dopamine neurons
0.1 μM, 1 μM
5 days
To assess the effect of BT13 on the survival of RET-knockout dopamine neurons. BT13 failed to influence the survival of RET-knockout embryonic midbrain dopamine neurons.
Mov Disord. 2020 Feb;35(2):245-255
Wild-type embryonic midbrain dopamine neurons
0.1 μM, 1 μM
5 days
To assess the effect of BT13 on the survival of cultured dopamine neurons. BT13 significantly increased the number of surviving wild-type embryonic midbrain dopamine neurons.
Mov Disord. 2020 Feb;35(2):245-255
MG87RET cells
25 μM
To evaluate the ability of BT13 to activate RET and signal via GFL receptors. BT13 significantly increased the phosphorylation level of RET in cells expressing GFR α1/RET and GFR α2/RET.
Administered on post-surgical days 1, 3, 5, 8, 10, and 12
BT13 attenuated mechanical hypersensitivity and reversed injury-induced changes in the expression of sensory neuron markers in dorsal root ganglia
Front Pharmacol. 2017 Jun 21;8:365
Mice
Not specified
Stereotactic injection into the striatum
103.5 μg, 207 μg, 517.5 μg, 776.25 μg
Single injection
To evaluate the ability of BT13 to activate intracellular signaling cascades in the mouse striatum. BT13 at the dose of 750μg significantly increased phosphorylation of ERK and S6.
搜索
